P1732RECURRENCE OF GLOMERULONEPHRITIS POST TRANSPLANT

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Umesh Lingaraj ◽  
Ricken Mehta ◽  
Shivaprasad SM ◽  
Kishan A ◽  
Leelavathi V ◽  
...  

Abstract Background and Aims Glomerulonephritis (GN) is a major cause of end stage renal disease (ESRD)1. It represents the primary cause of end stage renal disease (ESRD) for 25% of the dialysis population1 and 45% of the transplant population. For patients with GN requiring renal replacement therapy, kidney transplantation is associated with superior outcomes compared with dialysis2. The possibility of recurrence of the original disease after transplantation was described in a seminal paper more than 40 years ago, and it is now clear that all forms of GN may recur after kidney transplantation.3 To study the recurrence of glomerulonephritis post-transplant in a tertiary care centre. Method 120 renal transplant recipients were analyzed from September 2015 to August 2019 at the Institute of Nephro-Urology, Bangalore. It was a retrospective analysis of data Results 120 adult patients underwent kidney transplantation, out of these 70 had GN as primary cause of kidney disease. 85.8% were males, 14.2 % females. 58.9 % were biopsy proven GN, remaining 41.1 % diagnosed based on history and clinical presentation. All but one patient had their first transplant. Out of these kidney transplant recipients 08 (11.4%) had recurrence of GN.  From these 4/08 was recurrent IgA N, 2/08 were PGNMID, 1/08 MGN, 1/08 aHUS. Graft loss due to recurrent GN was seen in 1/08 patients (12.5%). Conclusion Our study showed that 11.4 % of kidney transplant recipients with GN as their cause of ESRD had recurrent GN post kidney transplantation. IgAN was the most type of GN that recurred most frequently followed by PGNMID. Recurrence of GN was in par with other studies and did not affect graft survival

2007 ◽  
Vol 39 (4) ◽  
pp. 1091-1094 ◽  
Author(s):  
J. Ameli ◽  
H. Kachuee ◽  
S. Assari ◽  
V.R. Rasta ◽  
H.R. Khoddami-Vishte ◽  
...  

Kidney360 ◽  
2021 ◽  
pp. 10.34067/KID.0002532021
Author(s):  
Maria Ajaimy ◽  
Luz Liriano-Ward ◽  
Jay A Graham ◽  
Enver Akalin

COVID-19 disease has significantly affected the transplant community by leading to decreased transplant activity and increased waiting list time. As expected, COVID-19 causes substantial mortality in both end-stage renal disease and kidney transplant populations. This is due to underlying chronic kidney disease and a high prevalence of comorbid conditions such as diabetes mellitus, hypertension, and cardiovascular disease in this group. Transplant programs have faced the difficult decision of weighing the risks and benefits of transplantation during the pandemic. On one hand there is a risk of COVID-19 exposure leading to infection while patients are on maximum immunosuppression. Alternatively, there are risks of delaying transplantation, which will increase waitlist-time and may lead to waitlist-associated morbidity and mortality. Cautious and thoughtful selection of both the recipient's and donor's post-transplant management is required during the pandemic to mitigate the risk of morbidity and mortality associated with COVID-19. In this review article we aimed to discuss previous publications related to clinical outcomes of COVID-19 disease in kidney transplant recipients, end-stage renal disease patients on dialysis or on the transplant waiting-list and precautions transplant centers should take in decision making for recipient and donor selection and immunosuppressive management during the pandemic. Nevertheless, transplantation in this milieu does seem to be the correct decision with a careful patient and donor selection with safeguard protocols for infection prevention. Each center should do risk assessment based on their patient's age and medical comorbidities, waitlist time, degree of sensitization, cold ischemia time, status of vaccination, and severity of pandemic in their region.


Sign in / Sign up

Export Citation Format

Share Document